Article
Substance Abuse
Robert P. Schwartz, Sharon M. Kelly, Shannon G. Mitchell, Kevin E. O'Grady, Tiffany Duren, Anjalee Sharma, Jan Gryczynski, Jerome H. Jaffe
Summary: This study compared the 24-month post-release outcomes of arrestees with opioid use disorder receiving three different treatment approaches and found no significant differences among the treatment conditions. The study suggests the need for continued research in finding more effective interventions for this population.
DRUG AND ALCOHOL DEPENDENCE
(2021)
Article
Medicine, General & Internal
Joshua D. Lee, Mia Malone, Ryan McDonald, Anna Cheng, Kumar Vasudevan, Babak Tofighi, Ann Garment, Barbara Porter, Keith S. Goldfeld, Michael Matteo, Jasdeep Mangat, Monica Katyal, Jonathan Giftos, Ross MacDonald
Summary: The study compared treatment retention between adults receiving daily sublingual buprenorphine-naloxone (SLB) and those receiving extended-release buprenorphine (XRB) following release from jail. The results showed that patients in the XRB group had higher community buprenorphine treatment retention rates compared to the SLB group.
Article
Multidisciplinary Sciences
Dara M. Kusic, Jessica Heil, Stefan Zajic, Andrew Brangan, Oluseun Dairo, Stacey Heil, Gerald Feigin, Sherri Kacinko, Russell J. Buono, Thomas N. Ferraro, Rachel Rafeq, Rachel Haroz, Kaitlan Baston, Elliot Bodofsky, Michael Sabia, Matthew Salzman, Alissa Resch, Jozef Madzo, Laura B. Scheinfeldt, Jean-Pierre J. Issa, Jaroslav Jelinek
Summary: The United States is facing a long-standing opioid misuse epidemic, exacerbated by the COVID-19 pandemic and the rising use of powerful synthetic opioids like fentanyl. The Camden Opioid Research Initiative (CORI) aims to study this complex issue, finding that co-occurring substance use is common among opioid toxicity deaths, while medication-assisted treatment is infrequently observed. Efforts to address the opioid misuse epidemic must consider the complexities of co-occurring stimulant and other substance use, and reduce the barriers and stigma associated with seeking effective medication-assisted treatments.
Article
Substance Abuse
Kelley N. Benck, Kapriskie Seide, Alexis K. Jones, Marisa Omori, Lauren Brinkley Rubinstein, Curt Beckwith, Kathryn M. Nowotny
Summary: Pregnant incarcerated persons have better access to medication for opioid use disorder (MOUD) compared to non-pregnant persons. Urban and larger jails are more likely to offer MOUD. However, post-incarceration linkage remains a challenge.
DRUG AND ALCOHOL DEPENDENCE
(2023)
Editorial Material
Substance Abuse
Justin Berk, Brandon del Pozo, Josiah D. Rich, Joshua D. Lee
Summary: As opioid overdose cases continue to rise, it is important for policy-makers and researchers to focus on interventions for high-risk populations. Incarceration is identified as a risk factor for opioid overdose, with many recent overdose deaths involving individuals who had encounters with the criminal justice system. In the prison and jail settings, there are unique administrative barriers that hinder access to medications for opioid use disorder. Extended-release buprenorphine can help overcome these barriers and provide practical advantages in correctional health delivery, potentially playing a crucial role in treating opioid addiction in carceral settings. Future research and policy discussions should explore the optimal role of extended-release buprenorphine in addressing opiate addiction in prisons.
JOURNAL OF ADDICTION MEDICINE
(2022)
Review
Substance Abuse
Dennis McCarty, Brian Chan, Christina Bougatsos, Sara Grusing, Roger Chou
Summary: This study reviewed the evidence on interim methadone and other strategies to reduce wait lists in opioid treatment programs (OTPs) and found that interim methadone may be effective, safe, and could increase access to OTPs.
DRUG AND ALCOHOL DEPENDENCE
(2021)
Article
Substance Abuse
Elizabeth A. Evans, Donna Wilson, Peter D. Friedmann
Summary: The study found that incarcerated individuals with opioid use disorder who were offered buprenorphine during their time in jail had a lower risk of recidivism after release.
DRUG AND ALCOHOL DEPENDENCE
(2022)
Article
Substance Abuse
Brian Corry, Natasha Underwood, Laura J. Cremer, Cherie R. Rooks-Peck, Christopher Jones
Summary: This study explores the association between sociodemographic factors and the availability of medications for opioid use disorder (MOUD). The findings show significant differences in the availability of opioid treatment programs (OTPs) and buprenorphine treatment at the county level, with variations related to demographic characteristics, poverty rates, drug overdose death rates, health insurance coverage, and disability rates.
DRUG AND ALCOHOL DEPENDENCE
(2022)
Article
Substance Abuse
Anna Cheng, Ryan Badolato, Andrew Segoshi, Ryan McDonald, Mia Malone, Kumar Vasudevan, Beita Badiei, Allison Sugarman, Ross Macdonald, Jasdeep Mangat, Jonathan Giftos, Joshua D. Lee, Babak Tofighi
Summary: This study explores the experiences of adults receiving extended-release buprenorphine (XRB) as a jail-to-community treatment for opioid use disorder. Key factors influencing initiation of XRB in jail included reducing stigma and privacy concerns, as well as positive influence of in-jail peer networks. Participants reported satisfaction with XRB treatment due to reduced clinic visits, perceived efficacy, and lower risk of drug-related criminal activities. However, barriers to retention included post-injection withdrawal symptoms and cravings.
ADDICTION SCIENCE & CLINICAL PRACTICE
(2022)
Review
Substance Abuse
Laura Samso Jofra, Teresa Puig, Ivan Sola, Joan Trujols
Summary: This study reviewed the impact of interim opioid agonist treatment (OAT) on treatment retention, access to standard OAT, quality of life, and satisfaction with treatment. The study found that interim treatment may be more effective than waiting lists in accessing treatment, and it may be as effective as standard treatment in terms of treatment retention.
HARM REDUCTION JOURNAL
(2022)
Article
Substance Abuse
Alexandria Macmadu, Joella W. Adams, S. E. Bessey, Lauren Brinkley-Rubinstein, Rosemarie A. Martin, Jennifer G. Clarke, Traci C. Green, Josiah D. Rich, Brandon D. L. Marshall
Summary: The study found that expanding access to medications for opioid use disorder (MOUD) in the prison system can significantly reduce post-release overdose mortality, especially with access to all three MOUD. However, the real-world impact will vary based on levels of incarceration, treatment enrollment, and post-release retention.
INTERNATIONAL JOURNAL OF DRUG POLICY
(2021)
Article
Psychiatry
Prianka Padmanathan, Harriet Forbes, Maria Theresa Redaniel, David Gunnell, Dan Lewer, Paul Moran, Ben Watson, Louisa Degenhardt, Matthew Hickman
Summary: The study found that opioid agonist treatment is associated with reduced risk of self-harm during treatment, but an increased risk of self-harm and suicide in the first month after treatment cessation.
Article
Substance Abuse
Barbara Andraka-Christou, M. H. Clark, Danielle N. Atkins, Brandon del Pozo
Summary: The survey found considerable policy variation, with more permissive policies for naltrexone than buprenorphine or methadone, and more permissive policies for continuing MOUD than for initiating MOUD or completing a court program with MOUD. Most judges indicated that MOUD is permitted sometimes or usually, with very few choosing never or always.
Article
Public, Environmental & Occupational Health
Milan F. F. Satcher, Martha L. L. Bruce, Daisy J. J. Goodman, Sarah E. E. Lord
Summary: This study examines the factors associated with timely prenatal care initiation and adequate prenatal care utilization among pregnant women with criminal legal involvement and opioid use disorder (CL-OUD). The results suggest that OUD treatment, comorbid indications for care, and stable access to social resources are important factors for supporting timely and adequate prenatal care among women with CL-OUD.
Article
Psychology, Clinical
Christopher J. Donelan, Edmond Hayes, Ruth A. Potee, Levin Schwartz, Elizabeth A. Evans
Summary: The Franklin County Sheriff's Office is among the first jails nationwide to provide correctional populations with access to all three medications to treat opioid use disorder, and they quickly implemented comprehensive mitigation policies and adapted MOUD programming in response to the COVID-19 pandemic. Two major challenges they faced were the rapid release of nonviolent pretrial individuals who were being treated with MOUD, and establishing physically distanced MOUD services in jail.
JOURNAL OF SUBSTANCE ABUSE TREATMENT
(2021)